BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 20031808)

  • 1. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
    Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is anyone too old for an implantable cardioverter-defibrillator?
    Heidenreich PA; Tsai V
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):6-8. PubMed ID: 20031806
    [No Abstract]   [Full Text] [Related]  

  • 3. Fragmented QRS and mortality risk in patients with left ventricular dysfunction.
    Cheema A; Khalid A; Wimmer A; Bartone C; Chow T; Spertus JA; Chan PS
    Circ Arrhythm Electrophysiol; 2010 Aug; 3(4):339-44. PubMed ID: 20511537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction.
    Chan PS; Chow T; Kereiakes D; Schloss EJ; Waller T; Eagle K; Hayward RA; Vijan S
    Arch Intern Med; 2006 Nov; 166(20):2228-33. PubMed ID: 17101941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.
    Nakhoul GN; Schold JD; Arrigain S; Harb SC; Jolly S; Wilkoff BL; Nally JV; Navaneethan SD
    Clin J Am Soc Nephrol; 2015 Jul; 10(7):1119-27. PubMed ID: 26111859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study.
    Filion KB; Xie X; van der Avoort CJ; Dendukuri N; Brophy JM
    Int J Technol Assess Health Care; 2009 Apr; 25(2):151-60. PubMed ID: 19331707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction.
    Forleo GB; Della Rocca DG; Papavasileiou LP; Panattoni G; Sergi D; Duro L; Mahfouz K; Magliano G; Santini L; Romeo F
    J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):779-84. PubMed ID: 21941203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age.
    Sanders GD; Kong MH; Al-Khatib SM; Peterson ED
    Am Heart J; 2010 Jul; 160(1):122-31. PubMed ID: 20598982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.
    Goldenberg I; Vyas AK; Hall WJ; Moss AJ; Wang H; He H; Zareba W; McNitt S; Andrews ML;
    J Am Coll Cardiol; 2008 Jan; 51(3):288-96. PubMed ID: 18206738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
    Cowie MR; Marshall D; Drummond M; Ferko N; Maschio M; Ekman M; de Roy L; Heidbuchel H; Verboven Y; Braunschweig F; Linde C; Boriani G
    Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.
    Stockburger M; Krebs A; Nitardy A; Habedank D; Celebi O; Knaus T; Dietz R
    Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S16-20. PubMed ID: 19250084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator.
    Roes SD; Borleffs CJ; van der Geest RJ; Westenberg JJ; Marsan NA; Kaandorp TA; Reiber JH; Zeppenfeld K; Lamb HJ; de Roos A; Schalij MJ; Bax JJ
    Circ Cardiovasc Imaging; 2009 May; 2(3):183-90. PubMed ID: 19808591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy.
    Chow T; Kereiakes DJ; Bartone C; Booth T; Schloss EJ; Waller T; Chung E; Menon S; Nallamothu BK; Chan PS
    J Am Coll Cardiol; 2007 Jan; 49(1):50-8. PubMed ID: 17207722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
    Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
    J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of gender on mortality or appropriate shock in patients with nonischemic cardiomyopathy who have implantable cardioverter-defibrillators.
    Chen HA; Hsia HH; Vagelos R; Fowler M; Wang P; Al-Ahmad A
    Pacing Clin Electrophysiol; 2007 Mar; 30(3):390-4. PubMed ID: 17367359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.
    Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting ventricular arrhythmias in patients with ischemic heart disease: clinical application of the ECG-derived QRS-T angle.
    Borleffs CJ; Scherptong RW; Man SC; van Welsenes GH; Bax JJ; van Erven L; Swenne CA; Schalij MJ
    Circ Arrhythm Electrophysiol; 2009 Oct; 2(5):548-54. PubMed ID: 19843923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure.
    Hernandez AF; Fonarow GC; Hammill BG; Al-Khatib SM; Yancy CW; O'Connor CM; Schulman KA; Peterson ED; Curtis LH
    Circ Heart Fail; 2010 Jan; 3(1):7-13. PubMed ID: 20009044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial.
    Barsheshet A; Goldenberg I; Moss AJ; Huang DT; Zareba W; McNitt S; Klein HU; Guetta V
    J Cardiovasc Electrophysiol; 2011 Nov; 22(11):1237-42. PubMed ID: 21615813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.